Colon Cancer

P2/3, N=124, Completed, Institut du Cancer de Montpellier - Val d'Aurelle | Phase classification: P3 --> P2/3

P=N/A, N=320, Recruiting, University of Colorado, Denver | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Jan 2026 --> Jan 2027

P1, N=57, Active, not recruiting, ModernaTX, Inc. | Recruiting --> Active, not recruiting

In COAD, a subset of patients in stage II/III with CD3+RUNX3+high/CD8 + high may be spared adjuvant treatment due to excellent prognosis. However, further studies are needed to confirm and elucidate the protective role of CD3+RUNX3+ cells in COAD and LUAD.

The electric fields enhance the electron transfer and amplify the electrochemiluminescence intensity, thereby achieving ultra-sensitive detection of the methylated Septin9 gene with a detection limit as low as 8.2 aM. Clinical sample validation using clinical serum samples from healthy controls (n = 100) and colon cancer patients (n = 100) has shown that the biosensor achieves comparable performance to the gold standard method in terms of both sensitivity and specificity, demonstrating equivalent detection efficacy to pyrosequencing.

P2, N=15, Recruiting, M.D. Anderson Cancer Center | Trial primary completion date: Feb 2026 --> Feb 2028

She started combination therapy with ipilimumab and nivolumab, achieving complete metabolic and imaging response as confirmed by PET-CT at 12 months...She started treatment with pembrolizumab, achieving a sustained complete response at 12 months...Both cases illustrate the remarkable clinical benefit of immunotherapy in patients with early peritoneal recurrence of MSI-H/dMMR colon cancer, which is usually associated with poor prognosis. These cases highlight the need to consider the molecular profile in therapeutic planning and reinforce the emerging value of immunotherapy as a cornerstone in the management of these cases.

Ectopic expressions of DNMT1 impose an epigenetic checkpoint at those target loci by methylation of promoter DNA of the respective genes. We conclude that, gene specific hypomethylation of some genes, including COL1A1, COL1A2, COL4A1, SPP1, SPARC, and THBS2 drives COAD and would serve as potential markers for COAD screening.

Preliminary functional assays also showed minimal impact on P-gp and OATP activity. While preliminary, this study provides a comprehensive evaluation of açaí-mediated modulation of key pharmacokinetic pathways and underscores the need for rigorous assessment of botanical extracts to better predict potential botanical-drug interactions.

A subset of patients with CC exhibits anxiety and depressive symptoms, which are significantly positively correlated with stress-related markers and CRF. Moreover, patients with CC, female patients, those aged 60 years or older, and patients diagnosed with stage III-IV tumors are more prone to anxiety or depression.

Our research results indicated that high-dose proton irradiation trigger the rejection of distal tumor colonization through a signaling pathway that depends on HMGB1. This research advanced our understanding of proton beam therapy immunological mechanisms and offered insights for improving tumor treatment outcomes.

Erastin (ER), a small-molecule compound, induces ferroptosis through ROS accumulation...Our findings highlight ASNS, CHAC1, PCK2, DDIT4, and ATF3/4 as potential biomarkers for ferroptosis in CRC. Monitoring the expression of these genes may help identify patients who are responsive to ferroptosis inducers and facilitate the development of personalized treatment strategies.